Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
EphB4 Goat anti-Human, Polyclonal, R&D Systems™
Goat Polyclonal Antibody has been used in 7 publications
Supplier: R&D Systems AF3038
This item is not returnable. View return policy
SDSDocumentsProduct Certifications Promotions
DescriptionEphB4 Polyclonal specifically detects EphB4 in Human samples. It is validated for Western Blot, Simple Western, Flow Cytometry, Immunohistochemistry, CyTOF-ready, Knockout Validated.
|Mouse myeloma cell line NS0-derived recombinant human EphB4 Leu16-Ala539 Accession # P54760|
|Detects human EphB4 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse (rm) EphB4 is observed and less than 1% cross-reactivity with recombinant human (rh) EphA4, rhEphA3, rhEphB2, and rhEphB3 is observed.|
|Western Blot, Flow Cytometry, Immunohistochemistry, CyTOF|
|Western Blot 2 ug/mL, Simple Western 50 ug/mL, Flow Cytometry 0.25 ug/10^6 cells, Immunohistochemistry 5-15 ug/mL, CyTOF-ready|
|EC 2.7.10, EC 126.96.36.199, EPH receptor B4, EphB4, ephrin type-B receptor 4, hepatoma transmembrane kinase, Htk, HTKephrin receptor EphB4, Mdk2, Myk1, soluble EPHB4 variant 1, soluble EPHB4 variant 2, soluble EPHB4 variant 3, Tyro11, Tyrosine-protein kinase receptor HTK, Tyrosine-protein kinase TYRO11|
|Reconstitute at 0.2 mg/mL in sterile PBS.|
|Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.|
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok